Conv. Plasma
Nigella Sativa

All curcumin studies
Meta analysis
study COVID-19 treatment researchCurcuminCurcumin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 50% Improvement Relative Risk Curcumin  Valizadeh et al.  LATE TREATMENT  DB RCT Is late treatment with curcumin beneficial for COVID-19? Double-blind RCT 40 patients in Iran Lower mortality with curcumin (not stat. sig., p=0.3) Valizadeh et al., Int. Immunopharmacol., Oct 2020 Favors curcumin Favors control

Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients

Valizadeh et al., Int. Immunopharmacol., doi:10.1016/j.intimp.2020.107088
Oct 2020  
  Source   PDF   All   Meta
Curcumin for COVID-19
14th treatment shown to reduce risk in February 2021
*, now known with p = 0.000000046 from 26 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments.
Small RCT with 40 nano-curcumin patients and 40 control patients showing lower mortality with treatment. Authors conclude that nano-curcumin may be able to modulate the increased rate of inflammatory cytokines especially IL-1β and IL-6 mRNA expression and cytokine secretion in COVID-19 patients, which may improve clinical outcomes.
This is the 1st of 20 COVID-19 RCTs for curcumin, which collectively show efficacy with p=0.0000093.
This is the 1st of 26 COVID-19 controlled studies for curcumin, which collectively show efficacy with p=0.000000046 (1 in 22 million).
risk of death, 50.0% lower, RR 0.50, p = 0.30, treatment 4 of 20 (20.0%), control 8 of 20 (40.0%), NNT 5.0.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Valizadeh et al., 20 Oct 2020, Double Blind Randomized Controlled Trial, Iran, peer-reviewed, 12 authors.
This PaperCurcuminAll
Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients
Hamed Valizadeh, Samaneh Abdolmohammadi-Vahid, Svetlana Danshina, Mehmet Ziya Gencer, Ali Ammari, Armin Sadeghi, Leila Roshangar, Saeed Aslani, Abdolreza Esmaeilzadeh, Mahnaz Ghaebi, Sepehr Valizadeh, Majid Ahmadi
International Immunopharmacology, doi:10.1016/j.intimp.2020.107088
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre -including this research content -immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Declaration of Competing Interest The authors declared that there is no conflict of interest. Appendix A. Supplementary material Supplementary data to this article can be found online at https://
Afolayan, Erinwusi, Oyeyemi, Immunomodulatory activity of curcuminentrapped poly d, l-lactic-co-glycolic acid nanoparticles in mice, Integrative Medicine Res
Aggarwal, Kumar, Bharti, Anticancer potential of curcumin: preclinical and clinical studies, Anticancer Res
Ay, Bakır, Bozkurt, Kayis, Hakki, Positive effect of curcumin on experimental peridontitis via suppression of IL-1-beta and IL-6 expression level, International Journal for Vitamin and Nutrition Research
Bose, Panda, Mukherjee, Sa, Curcumin and tumor immune-editing: resurrecting the immune system, Cell division
Cascella, Rajnik, Cuomo, Dulebohn, Napoli, Features, evaluation and treatment coronavirus (COVID-19)
Catanzaro, Corsini, Rosini, Racchi, Lanni, Immunomodulators inspired by nature: a review on curcumin and echinacea, Molecules
Conti, Ronconi, Caraffa, Gallenga, Ross et al., Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies, J. Biol. Regul. Homeost. Agents
Corkum, Ings, Burgess, Karwowska, Kroll et al., Immune cell subsets and their gene expression profiles from human PBMC isolated by Vacutainer Cell Preparation Tube (CPT™) and standard density gradient, BMC immunology
Dei Cas, Ghidoni, Dietary curcumin: correlation between bioavailability and health potential, Nutrients
Derosa, Maffioli, Simental-Mendia, Bo, Sahebkar, Effect of curcumin on circulating interleukin-6 concentrations: a systematic review and meta-analysis of randomized controlled trials, Pharmacol. Res
Dolati, Ahmadi, Aghebti-Maleki, Nikmaram, Marofi et al., Nanocurcumin is a potential novel therapy for multiple sclerosis by influencing inflammatory mediators, Pharmacol. Rep
Dolati, Ahmadi, Rikhtegar, Babaloo, Ayromlou et al., Changes in Th17 cells function after nanocurcumin use to treat multiple sclerosis, Int. Immunopharmacol
Feldmann, Maini, Woody, Holgate, Winter et al., Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed, The Lancet
Gera, Sharma, Ghosh, Huynh, Lee et al., Nanoformulations of curcumin: an emerging paradigm for improved remedial application, Oncotarget
Ghaebi, Osali, Valizadeh, Roshangar, Ahmadi, Vaccine development and therapeutic design for 2019-nCoV/SARS-CoV-2: Challenges and chances, Journal of cellular physiology
Gupta, Patchva, Aggarwal, Therapeutic roles of curcumin: lessons learned from clinical trials, AAPS J
Han, Ma, Li, Liu, Zhao et al., Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors, Emerging Microbes Infect
Hatamipour, Sahebkar, Alavizadeh, Dorri, Jaafari, Novel nanomicelle formulation to enhance bioavailability and stability of curcuminoids, Iranian J. Basic Medical Sci
Henry, De Oliveira, Benoit, Plebani, Lippi, Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis, Clinical Chem. Laboratory Medicine (CCLM)
Hewlings, Kalman, Curcumin: a review of its' effects on human health, Foods
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, The lancet
Li, Fan, Lai, Han, Li et al., Coronavirus infections and immune responses, J. Med. Virol
Li, Ma, Acute respiratory failure in COVID-19: is it "typical" ARDS?, Crit. Care
Marchetti, Swartzwelter, Koenders, Azam, Tengesdal et al., NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis, Arthritis Res. Therapy
Mouzaoui, Rahim, Djerdjouri, Aminoguanidine and curcumin attenuated tumor necrosis factor (TNF)-α-induced oxidative stress, colitis and hepatotoxicity in mice, Int. Immunopharmacol
Okabayashi, Kariwa, Yokota, Iki, Indoh et al., Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections, Journal of medical virology
Ruan, Yang, Wang, Jiang, Song, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive care medicine
Sahebkar, Cicero, Simental-Mendía, Aggarwal, Gupta, Curcumin downregulates human tumor necrosis factor-α levels: A systematic review and meta-analysis ofrandomized controlled trials, Pharmacol. Res
Schneider, Hossain, Vandermolen, Nicol, Comparison of remicade to curcumin for the treatment of Crohn's disease: A systematic review, Complementary Therapies Medicine
Taghizadieh, Mikaeili, Ahmadi, Valizadeh, Acute kidney injury in pregnant women following SARS-CoV-2 infection: A case report from Iran
Tay, Poh, Rénia, Macary, Ng, The trinity of COVID-19: immunity, inflammation and intervention, Nat. Rev. Immunol
Trivedi, Mondal, Gangwar, Jana, Immunomodulatory potential of nanocurcumin-based formulation, Inflammopharmacology
Ulhaq, Soraya, Interleukin-6 as a potential biomarker of COVID-19 progression
Wang, Yang, Li, Wen, Zhang, Clinical features of 69 cases with coronavirus disease 2019
Weiss, Leibowitz, Coronavirus pathogenesis, advances in virus research
Weiss, Navas-Martin, Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus, Microbiol. Mol. Biol. Rev
Yavarpour-Bali, Ghasemi-Kasman, Pirzadeh, Curcumin-loaded nanoparticles: A novel therapeutic strategy in treatment of central nervous system disorders, Int. J. Nanomed
Zhao, Liu, Yi, Wang, Qiao et al., Curcumin inhibiting Th17 cell differentiation by regulating the metabotropic glutamate receptor-4 expression on dendritic cells, Int. Immunopharmacol
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop